How can pharmacogenetic (PGx) testing help you personalize your patient’s care?
Results from pharmacogenetic testing provide actionable recommendations for gene-drug interactions to effectively treat your patient when initiating or modifying therapy.
PGx testing provides personalized genetic information to better understand how your patients respond to prescribed therapy for treatment of psychiatric and neurologic conditions.
Gain insight into metabolizer status for pharmacologic decision making
Shortcut the trial-and-error process for optimal drug response
Provide tools to assess alternative medication and dosage suggestions
"CYP2C9, CYP2C19, and CYP2D6 are involved in the metabolism of approximately 40% of routinely administered drugs." 1Verbeurgt P, Mamiya T, Oesterheld J. How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping. Pharmacogenomics 2014;15:655–65.
Aegis currently tests for the following genes: CYP2C19, CYP2D6, CYP2C9. Pharmacogenetic testing allows for identification of specific gene variants that may impact how behavioral health and pain management drugs affect patients. PGx testing looks for changes or variants in these genes that may determine whether a medication could be an effective treatment for your patient or whether your patient is prone to adverse effects.